stockrow
Friday 6 November 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024.
0.87
0.02
+2.35%
Follow AKAN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 0 | 3 | 0 | 1 | 0 | — | +161.8% | — | — | — | — | |
| Gross margin, % | — | — | — | 0.00 | (2,771.43) | (3.86) | 124.81 | 14.00 | 24.91 | (60.44) | — | (60.4) pt | ||||||
| EBT | — | — | — | (1) | (2) | (2) | (8) | (4) | (3) | (47) | — | +80.0% | ||||||
| EBT margin, % | — | — | — | 0.00 | (109,552.38) | (5,975.12) | (314.36) | (876.19) | (395.82) | (18,352.15) | — | (18,352.1) pt | ||||||
| Net income | — | 0 | — | (1) | (2) | (8) | (12) | (32) | (4) | (47) | (54) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 9.01 | 143.75 | 4,924.25 | 529.63 | 56.53 | 3.75 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.48) | (9,856.43) | (28,191.56) | (21,909.19) | (40,279.03) | (276.36) | (662.22) | — | +233.7% | ||||||
| Cash flow | — | — | — | (0.22) | (5,804.72) | (22,767.71) | (21,559.02) | (1,875.75) | (268.95) | (97.66) | 0.00 | +175.7% | ||||||
| Capex | — | — | — | 0.00 | (1,884.55) | (2,001.74) | (584.40) | 136.13 | (141.76) | (17.91) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.22) | (7,689.27) | (24,769.44) | (22,143.42) | (1,739.62) | (410.71) | (115.57) | 0.00 | +183.6% | ||||||
| Book value | — | — | — | 0.00 | (21,596.14) | (7,643.75) | 50,564.29 | (4,786.12) | 288.95 | (174.03) | 0.00 | n/m | ||||||
| Shares, m | — | — | — | 3 | 0 | 0 | 0 | 0 | 0 | 0 | — | (46.4%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | 0.00 | 0.00 | (0.11) | (0.17) | 0.08 | (0.68) | (0.59) | (0.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (7) | (11) | (2) | (4) | (7) | (14) | +47.9% | |||||
| Capex | — | — | — | (1) | 0 | (1) | 0 | 0 | (2) | (1) | (5) | +10.3% | ||||||
| Free cash flow | — | — | — | (1) | (2) | (7) | (12) | (1) | (6) | (8) | (18) | +52.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (3) | (4) | (6) | (8) | 1 | (3) | (10) | (0.1%) | |||||
| Net debt | — | — | — | — | 9 | 6 | 3 | 4 | (3) | 12 | 11 | +7.2% | ||||||
| Shareholders’ equity | — | — | — | — | (5) | (2) | 27 | (4) | 4 | (12) | (16) | +19.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (53.82) | (131.99) | (49.56) | (134.94) | (48.90) | (647.13) | 0.00 | (647.1) pt | |||||
| ROIC | — | — | — | — | (27.44) | (46.82) | (41.94) | 0.00 | (319.90) | (624.17) | 0.00 | (596.7) pt | ||||||
| ROE | — | — | — | 0.00 | 45.72 | 224.83 | (94.40) | (279.79) | (1,830.21) | 1,183.68 | 0.00 | +1,183.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 173 | 46 | 5 | 2 | 2 | — | (67.2%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.06 | 0.08 | 0.42 | 0.13 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jan 0001 · fundamentals updated 2 Nov 2026
Akanda Corp. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GELS Gelteq Limited | $4.9M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | |
| SBFM Sunshine Biopharma, Inc. | $2.1M | — (loss-making) | — (loss-making) | −1.56% (below 0%: shrinking) | n/m | +49.38% (above 0%: growing) | 26.20% | (17.41%) | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $2.0M | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| Median of peers | $3.1M | — | — | −1.56% | — | −2.68% | 35.15% | 0.00% |